Post Earnings Coverage as Stryker’s Quarterly Net Sales Soared 18.8%; Adjusted EPS Jumped 19.4%

Upcoming AWS Coverage on Medtronic

LONDON, UK / ACCESSWIRE / April 28, 2017 / Active Wall St. announces its post-earnings coverage on Stryker Corp. (NYSE: SYK). The Company disclosed its first quarter fiscal 2017 results on April 25, 2017. The medical technology Company outperformed sales and earnings expectations. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Stryker’s competitors within the Medical Appliances & Equipment space, Medtronic PLC (NYSE: MDT), is estimated to report earnings on May 30, 2017. AWS will be initiating a research report on Medtronic following the release of its next earnings results.

Today, AWS is promoting its earnings coverage on SYK; touching on MDT. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

For the three months ended March 31, 2017, Stryker’s consolidated net sales increased 18.4% as reported 18.8% in constant currency to $2.96 billion compared to net sales of $2.50 billion for Q1 2016. Excluding the 10.6% impact of acquisitions, the Company’s net sales in the reported quarter increased 8.2% in constant currency, including 9.2% from increased unit volume partially offset by 1.0% due to lower prices. The acquisition of Sage Products LLC and Physio-Control International, Inc. contributed $245 million to the Company’s consolidated net sales. Stryker’s sales numbers topped analysts’ consensus of $2.91 billion.

For Q1 2017, Stryker’s adjusted gross margin of 66.5% was down 150 basis points on a y-o-y basis. Compared to the year ago same period, the Company’s gross margin was unfavorably impacted primarily by acquisitions as well as business mix and foreign currency. The Company’s adjusted operating margin was 24.2% of sales for the reported quarter, essentially flat to the prior year’s same quarter.

Stryker’s reported net earnings of $444 million increased 10.4% compared to net earnings of $402 million in Q1 2016. The Company’s earnings per diluted share of $1.17 increased 9.3% compared to earnings of $1.07 per share in the year earlier same quarter. Reported net earnings include certain charges for the amortization of purchased intangible assets, Rejuvenate and ABG II and other recall matters, restructuring-related activities and acquisition and integration related activities. Excluding the impact of these items, adjusted net earnings of $560 million increased 19.7%, while on per share basis it surged 19.4% to $1.48. The Company’s earnings numbers surpassed Wall Street’s estimates of $1.43 per share.

Segment Results

During Q1 2017, Stryker’s MedSurg segment’s net sales surged 36.2% on reported and 36.6% in constant currency basis to $1.31 billion. Excluding the 25.8% impact of acquisitions, net sales in the reported quarter increased 10.8% in constant currency, including 9.8% from increased unit volume and 1.0% due to higher prices.

Stryker’s Orthopedics’ net sales grew 7.4% in Q1 2017 to $1.14 billion, as foreign currency exchange rates negatively impacted net sales by 0.4%. Excluding the 0.6% impact of acquisitions, the segment’s net sales in the reported quarter increased 7.2% in constant currency, including 9.9% from increased unit volume partially offset by 2.7% due to lower prices.

For Q1 2017, Stryker’s Neurotechnology and Spine segment generated met sales of $0.52 billion, up 7.3% as reported and 7.7% in constant currency basis. Excluding the 2.4% impact of acquisitions, net sales in the quarter increased 5.3% in constant currency, including 6.3% from increased unit volume partially offset by 1.0% due to lower prices.

Balance Sheet & Cash Flow

As of March 31, 2017, Stryker maintained a strong position, with $3.3 billion of cash and marketable securities, of which approximately 85% was held outside the US. Total debt on the balance sheet at the end of Q1 2017 $7.2 billion. The Company generated cash from operations of approximately $151 million. During the reported quarter, Stryker completed a $230 million share repurchase, which will offset the impact of dilution in 2017.

Outlook

For Fiscal 2017, Stryker reaffirmed organic sales growth forecast to be in the range of 5.5% – 6.5% and adjusted net earnings per diluted share to be in the range of $6.35 – $6.45. For Q2 2017, the Company expects adjusted net earnings per diluted share to be in the range of $1.48 – $1.52. On the basis of current levels of foreign currency exchange rates, the Company is predicting net sales in Q2 2017 and FY17 to be negatively impacted by approximately 1.0% and adjusted net earnings per diluted share to be negatively impacted by approximately $0.03 to $0.04 in Q2 2017 and $0.10 to $0.12 for the fiscal year.

Stock Performance

At the closing bell, on Thursday, April 27, 2017, Stryker’s stock slightly fell 0.60%, ending the trading session at $135.37. A total volume of 995.34 thousand shares were traded at the end of the day. In the last six months and previous twelve months, shares of the Company have surged 20.40% and 24.66%, respectively. Moreover, the stock gained 13.35% since the start of the year. The Company’s shares are trading at a PE ratio of 31.11 and have a dividend yield of 1.26%. At Thursday’s closing price, the stock’s net capitalization stands at $50.15 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 460965